NYC-based AI startup Paige launched OmniScreen, an AI-powered biomarker module that can evaluate more than 505 genes and identify 1,228 molecular biomarkers from standard pathology slides. The product analyzes digital images of cancer tissue slides to detect genetic mutations and biomarkers important in determining cancer types and guiding treatment decisions. OmniScreen is faster and more cost-effective than traditional gene sequencing methods, making it valuable for cancer research and therapy development. While currently available for research, Paige’s CEO believes OmniScreen could decrease the costs associated with gene analysis for precision medicine and improve cancer care.
Source link
Paige Launches AI Tool that Screens 505 Genes for Improved Cancer Diagnosis
